Answers are grounded in this paper and cite their sources.
Both ERG-rearranged and wild-type cancers had a significant improvement in rPFS with abiraterone acetate and prednisone in the COU-AA-302 trial. However, our data suggest that 2+ Edel cancers, accounting for 15% of all mCRPC patients and previously associated with a worse outcome, derived the greatest benefit.
No takes yet. Share an insight, caveat, or question.
Attard et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: